Статья
Согласительные междисциплинарные позиции наблюдательного комитета по метаболическому синдрому
.
1. Visseren FLJ, Mach F, Smulders YM, et al. 2021 ESC Guidelines on cardiovascular disease prevention in clinical practice. Eur J Prev Cardiol. 2022;29(1):5-115. doi:10.1093/eurjpc/zwab154.
2. Савина А. А., Фейгинова С. И. Распространенность ожирения среди населения Российской Федерации: период до пандемии COVID-19. Социальные аспекты здоровья населения [сетевое издание]. 2022;68(5):4. doi:10.21045/2071-5021-2022-68-5-4. EDN: EOYEAN.
3. Баланова Ю. А., Имаева А. Э., Куценко В. А. и др. Метаболический синдром и его ассоциации с социально-демографическими и поведенческими факторами риска в российской популяции 25-64 лет. Кардиоваскулярная терапия и профилактика. 2020;19(4):2600. doi:10.15829/1728-8800-2020-2600.
4. Бояринова М. А., Ротарь О. П., Ерина А. М. и др. Метаболически здоровое ожирение: предикторы трансформации в нездоровый фенотип в популяции жителей Санкт-Петербурга (по данным исследования ЭССЕ-РФ). Артериальная гипертензия. 2021;27(3):279-90. doi:10.18705/1607-419X-2021-27-3-279-290.
5. Grundy SM. Metabolic syndrome: a multiplex cardiovascular risk factor. J Clin Endocrinol Metab. 2007;92(2):399-404. doi:10.1210/jc.2006-0513.
6. Wang W, Hu M, Liu H, et al. Global Burden of Disease Study 2019 suggests that metabolic risk factors are the leading drivers of the burden of ischemic heart disease. Cell Metab. 2021;33(10):1943-56. doi:10.1016/j.cmet.2021.08.005.
7. Mendenhall E, Singer M. What constitutes a syndemic? Methods, contexts, and framing from 2019. Curr Opin HIV AIDS. 2020;15(4):213-7. doi:10.1097/COH.0000000000000628.
8. Singer M, Bulled N, Ostrach B. Whither syndemics?: Trends in syndemics research, a review 2015-2019. Glob Public Health. 2020;15(7):943-55. doi:10.1080/17441692.2020.1724317.
9. Singer M, Bulled N, Ostrach B, Mendenhall E. Syndemics and the biosocial conception of health. Lancet. 2017;389(10072):941-50. doi:10.1016/S0140-6736(17)30003-X.
10. Chong B, Kong G, Shankar K, et al. The global syndemic of metabolic diseases in the young adult population: A consortium of trends and projections from the Global Burden of Disease 2000-2019. Metabolism. 2023;141:155402. doi:10.1016/j.metabol.2023.155402.
11. Dobrowolski P, Prejbisz A, Kuryłowicz A, et al. Metabolic syndrome — a new definition and management guidelines: A joint position paper by the Polish Society of Hypertension, Polish Society for the Treatment of Obesity, Polish Lipid Association, Polish Association for Study of Liver, Polish Society of Family Medicine, Polish Society of Lifestyle Medicine, Division of Prevention and Epidemiology Polish Cardiac Society, "Club 30" Polish Cardiac Society, and Division of Metabolic and Bariatric Surgery Society of Polish Surgeons. Arch Med Sci. 2022;18(5):1133-56. doi:10.5114/aoms/152921.
12. Ndumele CE, Rangaswami J, Chow SL, et al. Cardiovascular-Kidney-Metabolic Health: A Presidential Advisory From the American Heart Association. Circulation. 2023;148(20):1606-35. doi:10.1161/CIR.0000000000001184.
13. Mechanick JI, Farkouh ME, Newman JD, Garvey WT. Cardiometabolic-Based Chronic Disease, Addressing Knowledge and Clinical Practice Gaps: JACC State-of-the-Art Review. J Am Coll Cardiol. 2020;75(5):539-55. doi:10.1016/j.jacc.2019.11.046.
14. Шляхто Е. В. Классификация сердечной недостаточности: фокус на профилактику. Российский кардиологический журнал. 2023;28(1):5351. doi:10.15829/1560-4071-2023-5351.
15. Manla Y, Almahmeed W. Cardiometabolic Clinics: Is There a Need for a Multidisciplinary Clinic? Front Clin Diabetes Healthc. 2022;3:880468. doi:10.3389/fcdhc.2022.880468.
16. Neeland IJ, Magwire ML, Kwun A, et al. Optimizing Care in Cardiovascular-Kidney-Metabolic Syndrome: Registry Data From the Cardiometabolic Center Alliance. Circ Popul Health Outcomes. 2026: e012828. doi:10.1161/CIRCOUTCOMES.125.012828.
17. Lloyd-Jones DM, Allen NB, Anderson CAM, et al. Life’s Essential 8: Updating and Enhancing the American Heart Association’s Construct of Cardiovascular Health: A Presidential Advisory From the American Heart Association. Circulation. 2022;146(5):e18-e43. doi:10.1161/CIR.0000000000001078.
18. National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. Circulation. 2002;106(25):3143-421.
19. American Heart Association; National Heart, Lung, and Blood Institue; Grundy SM, et al. Diagnosis and management of the metabolic syndrome. An American Heart Association/ National Heart, Lung, and Blood Institute Scientific Statement. Executive summary. Cardiol Rev. 2005;13(6):322-7.
20. Alberti KG, Zimmet P, Shaw J, et al. The metabolic syndrome — a new worldwide definition. Lancet. 2005;366(9491):1059-62. doi:10.1016/S0140-6736(05)67402-8.
21. Alberti KG, Zimmet P, Shaw J. Metabolic syndrome — a new world-wide definition. A Consensus Statement from the International Diabetes Federation. Diabet Med. 2006;23(5):469-80. doi:10.1111/j.1464-5491.2006.01858.x.
22. Fahed G, Aoun L, Bou Zerdan M, et al. Metabolic Syndrome: Updates on Pathophysiology and Management in 2021. Int J Mol Sci. 2022;23(2):786. doi:10.3390/ijms23020786.
23. Zyoud SH, Shakhshir M, Abushanab AS, et al. Mapping the knowledge structure of research on insulin resistance and metabolic syndrome: a global perspective. Translational Medicine Communications. 2024;9(6):1-13. doi:10.1186/s41231-024-00165-z.
24. Rabiee A, Hossain MA, Poojari A. Adipose Tissue Insulin Resistance: A Key Driver of Metabolic Syndrome Pathogenesis. Biomedicines. 2025;13(10):2376. doi:10.3390/biomedicines13102376.
25. Liu WN, Hsu YC, Lin YP, et al. Comparisons of various insulin resistance indices for new-onset metabolic syndrome before midlife: The CHIEF cohort study, 2014-2020. World J Diabetes. 2025;16(5):101840. doi:10.4239/wjd.v16.i5.101840.
26. McLaughlin T, Abbasi F, Cheal K, et al. Use of Metabolic Markers To Identify Overweight Individuals Who Are Insulin Resistant. Ann Intern Med. 2003;139(10):802-9. doi:10.7326/0003-4819-139-10-200311180-00007.
27. Irace C, Carallo C, Scavelli FB, et al. Markers of insulin resistance and carotid atherosclerosis. A comparison of the homeostasis model assessment and triglyceride glucose index. Int J Clin Pract. 2013;67(7):665-72. doi:10.1111/ijcp.1212.
28. Gounden V, Devaraj S, Jialal I. The role of the triglyceride-glucose index as a biomarker of cardio-metabolic syndromes. Lipids Health Dis. 2024;23(1):416. doi:10.1186/s12944-024-02412-6.
29. Jiang M, Li X, Wu H, et al. Triglyceride-Glucose Index for the Diagnosis of Metabolic Syndrome: A Cross-Sectional Study of 298,652 Individuals Receiving a Health Check-Up in China. Int J Endocrinol. 2022;2022:3583603. doi:10.1155/2022/3583603.
30. Song K, Xu Y, Wu S, et al. Research status of triglyceride glucose-body mass index (TyG-BMI index). Front Cardiovasc Med. 2025;12:1597112. doi:10.3389/fcvm.2025.1597112.
31. Duan M, Zhao X, Li S, et al. Metabolic score for insulin resistance (METS-IR) predicts all-cause and cardiovascular mortality in the general population: evidence from NHANES 2001-2018. Cardiovasc Diabetol. 2024;23(1):243. doi:10.1186/s12933-024-02334-8.
32. Zhou Z, Ding Q, Tang X, et al. Insulin Resistance Indices Predict Mortality in Cardiovascular Disease: A Large-Scale NHANES Study With Machine Learning Validation. Food Sci Nutr. 2025;13(11):e71080. doi:10.1002/fsn3.71080.
33. Azarboo A, Fallahtafti P, Jalali S, et al. Screening accuracy of Single-Point Insulin Sensitivity Estimator (SPISE) for metabolic syndrome: a systematic review and meta-analysis. BMC Endocr Disord. 2025;25(1):142. doi:10.1186/s12902-025-01957-6.
34. Seo MW, Cho W, Kim JY. The single point insulin sensitivity estimator (SPISE) index as a predictor of metabolic syndrome in Korean adults. Obes Res Clin Pract. 2023;17(3):198-202. doi:10.1016/j.orcp.2023.05.001.
35. Kosmas CE, Rodriguez Polanco S, Bousvarou MD, et al. The Triglyceride/High-Density Lipoprotein Cholesterol (TG/HDL-C) Ratio as a Risk Marker for Metabolic Syndrome and Cardiovascular Disease. Diagnostics (Basel). 2023;13(5):929. doi:10.3390/diagnostics13050929.
36. Azarpazhooh MR, Najafi F, Darbandi M, et al. Triglyceride/High-Density Lipoprotein Cholesterol Ratio: A Clue to Metabolic Syndrome, Insulin Resistance, and Severe Atherosclerosis. Lipids. 2021;56(4):405-12. doi:10.1002/lipd.12302.
37. Yin JL, Yang J, Song XJ, et al. Triglyceride-glucose index and health outcomes: an umbrella review of systematic reviews with meta-analyses of observational studies. Cardiovasc Diabetol. 2024;23(1):177. doi:10.1186/s12933-024-02241-y.
38. Dakota I, Huang W, Wijayanto MA, et al. Prognostic value of triglyceride-glucose index on predicting major adverse cardiovascular events in hypertensive patients: a systematic review and meta-analysis. Am J Prev Cardiol. 2025;22:100996. doi:10.1016/j.ajpc.2025.100996.
39. Xiao S, Zhang Q, Yang HY, et al. The association between triglyceride glucose-body mass index and all-cause and cardiovascular mortality in diabetes patients: a retrospective study from NHANES database. Sci Rep. 2024;14(1):13884. doi:10.1038/s41598-024-63886-z.
40. Su X, Rao H, Zhao C, et al. The association between the metabolic score for insulin resistance and mortality in patients with cardiovascular disease: a national cohort study. Front Endocrinol (Lausanne). 2024;15:1479980. doi:10.3389/fendo.2024.1479980.
41. Chen Y, Chang Z, Liu Y, et al. Triglyceride to high-density lipoprotein cholesterol ratio and cardiovascular events in the general population: A systematic review and meta-analysis of cohort studies. Nutrition, Metabolism and Cardiovascular Diseases. 2021;32:318-29. doi:10.1016/j.numecd.2021.11.005.
42. Blüher M. Obesity: global epidemiology and pathogenesis. Nat Rev Endocrinol. 2019;15:288-98. doi:10.1038/s41574-019-0176-8.
43. Stefan N, Häring HU, Hu FB, Schulze MB. Metabolically healthy obesity: epidemiology, mechanisms, and clinical implications. Lancet Diabetes Endocrinol. 2013;1(2):152-62. doi:10.1016/S2213-8587(13)70062-7.
44. Schulze MB, Stefan N. Metabolically healthy obesity: from epidemiology and mechanisms to clinical implications. Nat Rev Endocrinol. 2024;20:633-46. doi:10.1038/s41574-024-01008-5.
45. Gómez-Zorita S, Queralt M, Vicente MA, et al. Metabolically healthy obesity and metabolically obese normal weight: a review. J Physiol Biochem. 2021;77:175-89. doi:10.1007/s13105-020-00781-x.
46. Stefan N, Schick F, Häring H. Causes, Characteristics, and Consequences of Metabolically Unhealthy Normal Weight in Humans. Cell Metabolism. 2017;26:292-300. doi:10.1016/j.cmet.2017.07.008.
47. del Carmen De Anda Miranda M, Altamirano AA. Metabolic syndrome in adults: Diagnostic criteria. World Journal of Biology Pharmacy and Health Sciences. 2025;23(03):509-13. doi:10.30574/wjbphs.2025.23.3.0879.
48. Njomza N, Rona M, Flamur B, et al. The Role Of Insulin Resistance In Hypertension-The Pathophysiological Mechanisms. The Review of Diabetic Studies. 2025;21:921-33. doi:10.70082/d1n8fs33.
49. Obeidat AA, Ahmad MN, Ghabashi MA, et al. Developmental Trends of Metabolic Syndrome in the Past Two Decades: A Narrative Review. J Clin Med. 2025;14(7):2402. doi:10.3390/jcm14072402.
50. Yu ES, Hong K, Chun BC. Incidence and risk factors for progression from prehypertension to hypertension: a 12-year Korean Cohort Study. J Hypertens. 2020;38(9):1755-62. doi:10.1097/HJH.0000000000002494.
51. Kim SJ, Lee J, Nam CM, et al. Progression rate from new-onset pre-hypertension to hypertension in Korean adults. Circ J. 2011;75(1):135-40. doi:10.1253/circj.cj-09-0948.
52. Ma L, Li H, Zhuang H, et al. The Incidence of Metabolic Syndrome and the Valid Blood Pressure Cutoff Value for Predicting Metabolic Syndrome Within the Normal Blood Pressure Range in the Population Over 40 Years Old in Guiyang, China. Diabetes Metab Syndr Obes. 2021;14:2973-83. doi:10.2147/DMSO.S308923.
53. Han M, Li Q, Liu L, et al. Prehypertension and risk of cardiovascular diseases: a metaanalysis of 47 cohort studies. J Hypertens. 2019;37(12):2325-32. doi:10.1097/HJH.0000000000002191.
54. Huang Y, Wang S, Cai X, et al. Prehypertension and incidence of cardiovascular disease: a meta-analysis. BMC Med. 2013;11:177. doi:10.1186/1741-7015-11-177.
55. Huang Y, Cai X, Liu C, et al. Prehypertension and the risk of coronary heart disease in Asian and Western populations: a meta-analysis. J Am Heart Assoc. 2015;4(2):e001519. doi:10.1161/JAHA.114.001519.
56. Huang Y, Cai X, Li Y, et al. Prehypertension and the risk of stroke: a meta-analysis. Neurology. 2014;82(13):1153-61. doi:10.1212/WNL.0000000000000268.
57. Huang Y, Cai X, Zhang J, et al. Prehypertension and Incidence of ESRD: a systematic review and meta-analysis. Am J Kidney Dis. 2014;63(1):76-83. doi:10.1053/j.ajkd.2013.07.024.
58. Huang Y, Su L, Cai X, et al. Association of all-cause and cardiovascular mortality with prehypertension: a meta-analysis. Am Heart J. 2014;167(2):160-8. doi:10.1016/j.ahj.2013.10.023.
59. Kim MJ, Lim NK, Choi SJ, Park HY. Hypertension is an independent risk factor for type 2 diabetes: the Korean genome and epidemiology study. Hypertens Res. 2015;38(11):783-9. doi:10.1038/hr.2015.72.
60. Ma C, Zhai L, Huo RR, Liu YH. Joint associations of pre-diabetes, pre-hypertension, and pre-dyslipidemia with cardiovascular and metabolic disease progression. Diabetol Metab Syndr. 2025;17(1):310. doi:10.1186/s13098-025-01896-1.
61. Li Y, Xia P, Xu L, et al. A Meta-Analysis on Prehypertension and Chronic Kidney Disease. PLoS One. 2016;11(6):e0156575. doi:10.1371/journal.pone.0156575.
62. King DE, Egan BM, Mainous AG 3rd, Geesey ME. Elevation of C-reactive protein in people with prehypertension. J Clin Hypertens (Greenwich). 2004;6(10):562-8. doi:10.1111/j.1524-6175.2004.03577.x.
63. Fu J, Liu Y, Zhang L, et al. Nonpharmacologic Interventions for Reducing Blood Pressure in Adults With Prehypertension to Established Hypertension. J Am Heart Assoc. 2020;9(19): e016804. doi:10.1161/JAHA.120.016804.
64. Henkin JS, Pinto RS, Machado CLF, Wilhelm EN. Chronic effect of resistance training on blood pressure in older adults with prehypertension and hypertension: A systematic review and meta-analysis. Exp Gerontol. 2023;177:112193. doi:10.1016/j.exger.2023.112193.
65. Julius S, Nesbitt SD, Egan BM, et al.; Trial of Preventing Hypertension (TROPHY) Study Investigators. Feasibility of treating prehypertension with an angiotensin-receptor blocker. N Engl J Med. 2006;354(16):1685-97. doi:10.1056/NEJMoa060838.
66. Mirhosseini SA, Abdollahi A, Sayadi M, et al. Intensive blood pressure control to prevent major cardiovascular events in individuals with high-normal blood pressure (prehypertension): PRINT-TAHA9 randomized clinical trial. Clin Hypertens. 2026;32:e4. doi:10.5646/ch.2026.32.e4.
67. McEvoy JW, McCarthy CP, Bruno RM, et al. 2024 ESC Guidelines for the management of elevated blood pressure and hypertension. Eur Heart J. 2024;45(38):3912-4018. doi:10.1093/eurheartj/ehae178.
68. Writing Committee Members, Jones DW, Ferdinand KC, et al. 2025 AHA/ACC/AANP/ AAPA/ABC/ACCP/ACPM/AGS/AMA/ASPC/NMA/PCNA/SGIM Guideline for the Prevention, Detection, Evaluation and Management of High Blood Pressure in Adults: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. Circulation. 2025;152(11):e114-e218. doi:10.1161/CIR.0000000000001356.
69. Кобалава Ж. Д., Конради А. О., Недогода С. В. и др. Артериальная гипертензия у взрослых. Клинические рекомендации 2024. Российский кардиологический журнал. 2024;29(9):6117. doi:10.15829/1560-4071-2024-6117. EDN: GUEWLU.
70. Lin L, Tan W, Pan X, et al. Metabolic Syndrome-Related Kidney Injury: A Review and Update. Front. Endocrinol. 2022,13:904001. doi:10.3389/fendo.2022.904001.
71. Alberti KGM, Eckel RH, Grundy SM, et al. Harmonizing the Metabolic Syndrome: A joint Interim Statement of the Internatonal Diabetes Federation Task Force on Epidemiology and Prevention; National Heart, Lung, and Blood Institute; American Heart Association; World Heart Federation; International Atherosclerosis Society; and International Association for the Study of Obesity. Circulation. 2009;120:1640-5.
72. Osadnik K, Osadnik T, Gierlotka M, et al. Metabolic syndrome is associated with similar long-term prognosis in those living with and without obesity: an analysis of 45 615 patients from the nationwide LIPIDOGRAM 2004-2015 studies. Eur J Prev Cardiol. 2023;30(12):1195-204. doi:10.1093/eurjpc/zwad101.
73. Недогода С. В., Цыганкова О. В. Избыточная масса тела и ожирение при метаболическом синдроме. Российский кардиологический журнал. 2025;30(1S):6535. doi:10.15829/1560-4071-2025-6535. EDN: PLLCVQ.
74. American Diabetes Association Professional Practice Committee for Obesity; Screening, Diagnosis, Evaluation, and Staging of Obesity in Adults: Standards of Care in Overweight and Obesity — 2026. Diabetes, Obesity, and CardioMetabolic CARE. 2026; doci260003. doi:10.2337/doci26-0003.
75. Gutin I. In BMI We Trust: Reframing the Body Mass Index as a Measure of Health. Soc Theory Health. 2018;16(3):256-71. doi:10.1057/s41285-017-0055-0.
76. Khanna D, Peltzer C, Kahar P, Parmar MS. Body Mass Index (BMI): A Screening Tool Analysis. Cureus. 2022;14(2): e22119. doi:10.7759/cureus.22119.
77. Prospective Studies Collaboration; Whitlock G, Lewington S, et al. Body-mass index and cause-specific mortality in 900000 adults: collaborative analyses of 57 prospective studies. Lancet. 2009;373(9669):1083-96. doi:10.1016/S0140-6736(09)60318-4.
78. Global BMI Mortality Collaboration; Di Angelantonio E, Bhupathiraju SN, et al. Body-mass index and all-cause mortality: individual-participantdata meta-analysis of 239 prospective studies in four continents. Lancet. 2016;388:776-86. doi:10.1016/S0140-6736(16)30175-1.
79. Kivimäki M, Kuosma E, Ferrie JE, et al. Overweight, obesity, and risk of cardiometabolic multimorbidity: pooled analysis of individual-level data for 120813 adults from 16 cohort studies from the USA and Europe. Lancet Public Health. 2017;2(6):e277-e285. doi:10.1016/S2468-2667(17)30074-9.
80. Fallahtafti P, Soleimani H, Khanmohammadi S, et al. Global trends in cardiovascular mortality attributable to high body mass index: 1990-2021 analysis with future projections. Am J Prev Cardiol. 2025;24:101326. doi:10.1016/j.ajpc.2025.101326.
81. Hasan B, Nayfeh T, Alzuabi M, et al. Weight Loss and Serum Lipids in Overweight and Obese Adults: A Systematic Review and Meta-Analysis. J Clin Endocrinol Metab. 2020;105(12): dgaa673. doi:10.1210/clinem/dgaa673.
82. Grams J, Garvey WT. Weight Loss and the Prevention and Treatment of Type 2 Diabetes Using Lifestyle Therapy, Pharmacotherapy, and Bariatric Surgery: Mechanisms of Action. Curr Obes Rep. 2015;4(2):287-302. doi:10.1007/s13679-015-0155-x.
83. Labraña AM, Durán E, Martínez MA, et al. Menor peso corporal, de índice de masa corporal y de perímetro de cintura se asocian a una disminución en factores de riesgo cardiovascular en población chilena: Findings from the Chilean health surveyç [Effects of a lower body weight or waist circumference on cardiovascular risk]. Rev Med Chil. 2017;145(5):585-94. Spanish. doi:10.4067/S0034-98872017000500005.
84. Wing RR, Bolin P, Brancati FL, et al. Cardiovascular effects of intensive lifestyle intervention in type 2 diabetes. N Engl J Med. 2013;369(2):145-54. doi:10.1056/NEJMoa1212914.
85. Look AHEAD Research Group; Pi-Sunyer X, Blackburn G, et al. Reduction in weight and cardiovascular disease risk factors in individuals with type 2 diabetes: one-year results of the look AHEAD trial. Diabetes Care. 2007;30(6):1374-83. doi:10.2337/dc07-0048.
86. Ribisl PM, Gaussoin SA, Lang W, et al. Lifestyle intervention improves heart rate recovery from exercise in adults with type 2 diabetes: results from the Look AHEAD study. J Obes. 2012;2012:309196. doi:10.1155/2012/309196.
87. Kuna ST, Reboussin DM, Borradaile KE, et al. Long-term effect of weight loss on obstructive sleep apnea severity in obese patients with type 2 diabetes. Sleep. 2013;36(5):641-649A. doi:10.5665/sleep.2618.
88. Lazo M, Solga SF, Horska A, et al. Effect of a 12-month intensive lifestyle intervention on hepatic steatosis in adults with type 2 diabetes. Diabetes Care. 2010;33(10):2156-63. doi:10.2337/dc10-0856.
89. Belalcazar LM, Haffner SM, Lang W, et al. Lifestyle intervention and/or statins for the reduction of C-reactive protein in type 2 diabetes: from the look AHEAD study. Obesity (Silver Spring). 2013;21(5):944-50. doi:10.1002/oby.20431.
90. Morales E, Praga M. The effect of weight loss in obesity and chronic kidney disease. Curr Hypertens Rep. 2012;14(2):170-6. doi:10.1007/s11906-012-0247-x.
91. Wang Y, Chen Z, Huo Z, et al. Metabolic Syndrome Evolution and Cardio-Kidney-Metabolic Multimorbidity: Implications for Targeted Prevention. JACC Adv. 2025;4(6 Pt 2):101778. doi:10.1016/j.jacadv.2025.101778.
92. Алгоритмы специализированной медицинской помощи больным сахарным диабетом. Под редакцией И. И. Дедова, М. В. Шестаковой, О. Ю. Сухаревой. 12-й выпуск. М.; 2025.
93. Диагностика, лечение и диспансерное наблюдение пациентов с предиабетом в условиях первичной медико-санитарной помощи / Шестакова М. В., Драпкина О. М., Бакулин И. Г. и др. М.: ФГБУ "НМИЦ ТПМ" Минздрава России, 2021 г., 40 с.
94. Cai X, Zhang Y, Li M, et al. Association between prediabetes and risk of all cause mortality and cardiovascular disease: updated meta-analysis. BMJ. 2020;370:m2297. doi:10.1136/bmj.m2297.
95. Hyun MK, Park JH, Kim KH, et al. Incidence and Risk Factors for Progression to Diabetes Mellitus: A Retrospective Cohort Study. Int J Environ Res Public Health. 2021;19(1):123. doi:10.3390/ijerph19010123.
96. Harati H, Hadaegh F, Tohidi M, Azizi F. Impaired fasting glucose cutoff value of 5.6 mmol/l combined with other cardiovascular risk markers is a better predictor for incident Type 2 diabetes than the 6.1 mmol/l value: Tehran lipid and glucose study. Diabetes Res Clin Pract. 2009;85(1):90-5. doi:10.1016/j.diabres.2009.04.006.
97. Sune MP, Sune M, Sune P, Dhok A. Prevalence of Retinopathy in Prediabetic Populations: A Systematic Review and Meta-Analysis. Cureus. 2023;15(11): e49602. doi:10.7759/cureus.49602.
98. Wong TY, Liew G, Tapp RJ, et al. Relation between fasting glucose and retinopathy for diagnosis of diabetes: three population-based cross-sectional studies. Lancet. 2008;371(9614):736-43. doi:10.1016/S0140-6736(08)60343-8.
99. Kumar MR, Kumar BA, Alapati SD. A study of prevalence of microalbuminuria and retinopathy in pre-diabetic patients presenting to a tertiary care centre. Eur J Mol Clin Med. 2021;8:1-6.
100. Gabriel R, Boukichou Abdelkader N, Acosta T, et al. Early prevention of diabetes microvascular complications in people with hyperglycaemia in Europe. ePREDICE randomized trial. Study protocol, recruitment and selected baseline data. PLoS One. 2020;15(4): e0231196. doi:10.1371/journal.pone.0231196.
101. Dyck PJ, Clark VM, Overland CJ, et al. Impaired glycemia and diabetic polyneuropathy: the OC IG Survey. Diabetes Care. 2012;35(3):584-91. doi:10.2337/dc11-1421.
102. Liu X, Wu S, Song Q, Wang X. Reversion From Pre-Diabetes Mellitus to Normoglycemia and Risk of Cardiovascular Disease and All-Cause Mortality in a Chinese Population: A Prospective Cohort Study. J Am Heart Assoc. 2021;10(3): e019045. doi:10.1161/JAHA.120.019045.
103. Шальнова С. А., Метельская В. А., Куценко В. А. и др. Холестерин, не входящий в состав липопротеинов высокой плотности: современный ориентир оценки нарушений липидного обмена. Рациональная Фармакотерапия в Кардиологии. 2022;18(4):366-75. doi:10.20996/1819-6446-2022-07-01.
104. Бубнова М. Г., Ежов М. В., Аронов Д. М. и др. Гипертриглицеридемия (триглицеридбогатые липопротеины и их ремнанты): роль в развитии атеросклеротических сердечно-сосудистых заболеваний и стратегия контроля. Заключение Комитета экспертов Российского кардиологического общества (РКО), Национального общества по изучению атеросклероза (НОА), Российского общества кардиосоматической реабилитации и вторичной профилактики (РосОКР). Российский кардиологический журнал. 2025;30(5):6364. doi:10.15829/1560-4071-2025-6364. EDN: VNFGFQ.
105. Miller M, Ginsberg HN, Schaefer EJ. Relative atherogenicity and predictive value of non-high-density lipoprotein cholesterol for coronary heart disease. Am J Cardiol. 2008;101(7):1003-8. doi:10.1016/j.amjcard.2007.11.046.
106. Orakzai SH, Nasir K, Blaha M, et al. Non-HDL cholesterol is strongly associated with coronary artery calcification in asymptomatic individuals. Atherosclerosis. 2009;202(1):289-95. doi:10.1016/j.atherosclerosis.2008.03.014.
107. Lu W, Resnick HE, Jablonski KA, et al. Non-HDL cholesterol as a predictor of cardiovascular disease in type 2 diabetes: the strong heart study. Diabetes Care. 2003;26(1):16-23. doi:10.2337/diacare.26.1.16.
108. Liu J, Sempos CT, Donahue RP, et al. Non-high-density lipoprotein and very-low-density lipoprotein cholesterol and their risk predictive values in coronary heart disease. Am J Cardiol. 2006;98(10):1363-8. doi:10.1016/j.amjcard.2006.06.032.
109. Ridker PM, Rifai N, Cook NR, et al. Non-HDL cholesterol, apolipoproteins A-I and B100, standard lipid measures, lipid ratios, and CRP as risk factors for cardiovascular disease in women. JAMA. 2005;294(3):326-33. doi:10.1001/jama.294.3.326.
110. Bittner V, Hardison R, Kelsey SF, et al. Non-high-density lipoprotein cholesterol levels predict five-year outcome in the Bypass Angioplasty Revascularization Investigation (BARI). Circulation. 2002;106(20):2537-42. doi:10.1161/01.cir.0000038496.57570.06.
111. Ray KK, Cannon CP, Cairns R, et al. Prognostic utility of apoB/AI, total cholesterol/HDL, non-HDL cholesterol, or hs-CRP as predictors of clinical risk in patients receiving statin therapy after acute coronary syndromes: results from PROVE IT-TIMI 22. Arterioscler Thromb Vasc Biol. 2009;29(3):424-30. doi:10.1161/ATVBAHA.108.181735.
112. Cui Y, Blumenthal RS, Flaws JA, et al. Non-high-density lipoprotein cholesterol level as a predictor of cardiovascular disease mortality. Arch Intern Med. 2001;161(11):1413-9. doi:10.1001/archinte.161.11.1413.
113. Boekholdt SM, lt BJ, Mora S, et al. Association of LDL cholesterol, non-HDL cholesterol, and apolipoprotein B levels with risk of cardiovascular events among patients treated with statins: a meta-analysis. JAMA. 2012;307(12):1302-9. doi:10.1001/jama.2012.366.
114. Stürzebecher PE, Katzmann JL, Laufs U. What is ‘remnant cholesterol’? Eur Heart J. 2023;44(16):1446-8. doi:10.1093/eurheartj/ehac783.
115. Raja V, Aguiar C, Alsayed N, et al. Non-HDL-cholesterol in dyslipidemia: Review of the state-of-the-art literature and outlook. Atherosclerosis. 2023;383:117312. doi:10.1016/j.atherosclerosis.2023.117312.
116. Arsenault BJ, Rana JS, Stroes ES, et al. Beyond low-density lipoprotein cholesterol: respective contributions of non-high-density lipoprotein cholesterol levels, triglycerides, and the total cholesterol/high-density lipoprotein cholesterol ratio to coronary heart disease risk in apparently healthy men and women. J Am Coll Cardiol. 2009;55(1):35-41. doi:10.1016/j.jacc.2009.07.057.
117. Brunner FJ, Waldeyer C, Ojeda F, et al. Application of non-HDL cholesterol for population-based cardiovascular risk stratification: results from the Multinational Cardiovascular Risk Consortium. Lancet. 2019;394(10215):2173-83. doi:10.1016/S0140-6736(19)32519-X.
118. Mach F, Baigent C, Catapano AL, et al. 2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk: The Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and European Atherosclerosis Society (EAS). Eur Heart J. 2020;41(1):111-88. doi:10.1093/eurheartj/ehz455.
119. Гуревич В. С., Козиолова Н. А., Ежов М. В. и др. Нерешенные проблемы дислипидемии и резидуального сердечно-сосудистого риска. Атеросклероз и дислипидемии. 2022;(1):31-9. doi:10.34687/2219-8202.JAD.2022.01.0003.
120. Кухарчук В. В., Ежов М. В., Сергиенко И. В. и др. Диагностика и коррекция нарушений липидного обмена с целью профилактики и лечения атеросклероза. Российские рекомендации, VII пересмотр. Атеросклероз и дислипидемии. 2020;(1):7-42. doi:10.34687/2219-8202.JAD.2020.01.0002.
121. Rose G. The Strategy of Preventive Medicine. Oxford University Press. 1992. p. 171.
122. Baratta F, Cocomello N, Coronati M, et al. Cholesterol Remnants, Triglyceride-Rich Lipoproteins and Cardiovascular Risk. Int J Mol Sci. 2023;24(5):4268. doi:10.3390/ijms24054268.
123. Castelli WP. Epidemiology of triglycerides: a view from Framingham. American J Cardiol. 1992;70(19): H3-H9. doi:10.1016/0002-9149(92)91083-g.
124. Raposeiras-Roubin S, Rosselló X, Oliva B, et al. Triglycerides and residual atherosclerotic risk. J Am Coll Cardiol. 2021;77:3031-41. doi:10.1016/j.jacc.2021.04.059.
125. Toth PP, Fazio S, Wong ND, et al. Risk of cardiovascular events in patients with hypertriglyceridaemia: A review of real-world evidence. Diabetes Obes Metab. 2020;22(3):279-89. doi:10.1111/dom.13921.
126. Aaseth E, Halvorsen S, Helseth R, Gravning J. Remnant cholesterol, plasma triglycerides, and risk of cardiovascular disease events in young adults: a prospective cohort study. Eur J Prev Cardiol. 2025;32(13):1181-9. doi:10.1093/eurjpc/zwaf104.
127. Castañer O, Pintó X, Subirana I, et al. Remnant Cholesterol, Not LDL Cholesterol, Is Associated With Incident Cardiovascular Disease. J Am Coll Cardiol. 2020;76(23):2712-24. doi:10.1016/j.jacc.2020.10.008.
128. Liu J, Zeng FF, Liu ZM, et al. Effects of blood triglycerides on cardiovascular and all-cause mortality: a systematic review and meta-analysis of 61 prospective studies. Lipids Health Dis. 2013;12:159. doi:10.1186/1476-511X-12-159.
129. Arca M, Veronesi C, D’Erasmo L, et al. Association of Hypertriglyceridemia with All-Cause Mortality and Atherosclerotic Cardiovascular Events in a Low-Risk Italian Population: The TG-REAL Retrospective Cohort Analysis. J Am Heart Assoc. 2020;9: e015801. doi:10.1161/JAHA.119.015801.
130. Yuan S, Tang B, Zheng J, Larsson SC. Circulating Lipoprotein Lipids, Apolipoproteins and Ischemic Stroke. Ann Neurol. 2020;88(6):1229-36. doi:10.1002/ana.25916.
131. Huang YQ, Huang JY, Liu L, et al. Relationship between triglyceride levels and ischaemic stroke in elderly hypertensive patients. Postgrad Med J. 2020;96(1133):128-33. doi:10.1136/postgradmedj-2019-136961.
132. Ежов М. В., Кухарчук В. В., Сергиенко И. В. и др. Нарушения липидного обмена. Клинические рекомендации 2023. Российский кардиологический журнал. 2023;28(5):5471. doi:10.15829/1560-4071-2023-5471.
133. Mach F, Koskinas KC, Roeters van Lennep JE, et al. 2025 Focused Update of the 2019 ESC/EAS Guidelines for the management of dyslipidaemias. Eur Heart J. 2025;46(42):4359-78. doi:10.1093/eurheartj/ehaf190.
134. Writing Committee Members; Blumenthal RS, Morris PB, et al. 2026 ACC/AHA/AACVPR/ABC/ ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Dyslipidemia: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. Circulation. 2026;153(17): e1154-e1276. doi:10.1161/CIR.0000000000001423. Erratum in: Circulation. 2026;153(25): e1447. doi:10.1161/CIR.0000000000001457.
135. Langlois MR, Sniderman AD. Non-HDL Cholesterol or apoB: Which to Prefer as a Target for the Prevention of Atherosclerotic Cardiovascular Disease? Curr Cardiol Rep. 2020;22:67. doi:10.1007/s11886-020-01323-z.
136. Ginsberg HN, Packard CJ, Chapman MJ, et al. Triglyceride-rich lipoproteins and their remnants: metabolic insights, role in atherosclerotic cardiovascular disease, and emerging therapeutic strategies-a consensus statement from the European Atherosclerosis Society. Eur Heart J. 2021;42(47):4791-806. doi:10.1093/eurheartj/ehab551.
137. Zhao Y, Zhuang Z, Li Y, et al. Elevated blood remnant cholesterol and triglycerides are causally related to the risks of cardiometabolic multimorbidity. Nat Commun. 2024;15(1):2451. doi:10.1038/s41467-024-46686-x.
138. Schuitema PCE, Visseren FLJ, Nordestgaard BG, et al. Elevated triglycerides are related to higher residual cardiovascular disease and mortality risk independent of lipid targets and intensity of lipid-lowering therapy in patients with established cardiovascular disease. Atherosclerosis. 2025;408:120411. doi:10.1016/j.atherosclerosis.2025.120411.
139. Yuan H, Yu C, Li X, et al. Serum Uric Acid Levels and Risk of Metabolic Syndrome: A Dose-Response Meta-Analysis of Prospective Studies. J Clin Endocrinol Metab. 2015;100(11):4198-207. doi:10.1210/jc.2015-2527.
140. Raya-Cano E, Vaquero-Abellán M, Molina-Luque R, et al. Association between metabolic syndrome and uric acid: a systematic review and meta-analysis. Sci Rep. 2022;12(1):18412. doi:10.1038/s41598-022-22025-2.
141. Zhang Z, Pang Y, Shen J, et al. The new definition of metabolic syndrome including hyperuricemia improves its prognostic value: results from NHANES database. BMC Cardiovasc Disord. 2025;25(1):93. doi:10.1186/s12872-025-04529-7.
142. Borghi C, Domienik-Karłowicz J, Tykarski A, et al. Expert consensus for the diagnosis and treatment of patient with hyperuricemia and high cardiovascular risk: 2021 update. Cardiol J. 2021;28(1):1-14. doi:10.5603/CJ.a2021.0001.
143. Johnson R, Gruev I, Yotov Y, et al. Expert consensus for the diagnosis and treatment of patients with hyperuricemia and high cardiovascular risk: 2025 update. Eur J Intern Med. 2026:106727. doi:10.1016/j.ejim.2026.106727.
144. Блинова Н. В., Трушина О. Ю., Кисляк О. А. и др. Консенсус по ведению пациентов с гиперурикемией и высоким сердечно-сосудистым риском: 2025. Системные гипертензии. 2025;22(2):5-17. doi:10.38109/2075-082X-2025-2-5-17.
145. Virdis A, Masi S, Casiglia E, et al. Identification of the Uric Acid Thresholds Predicting an Increased Total and Cardiovascular Mortality Over 20 Years. Hypertension. 2020;75(2):302-8. doi:10.1161/HYPERTENSIONAHA.119.13643.
146. Jiang H, Su Y, Liu R, et al. Hyperuricemia and the risk of stroke incidence and mortality: A systematic review and meta-analysis. Arch Rheumatol. 2025;40(1):128-43. doi:10.46497/ArchRheumatol.2025.10808.
147. Casiglia E, Virdis A, Tikhonoff V, et al. Prognostic cut-off values of serum uric acid associated with fatal and non fatal incident myocardial infarction independently of arterial hypertension in a large cohort. J Hypertens. 2019;37: e221.
148. Casiglia E, Tikhonoff V, Virdis A, et al. Serum uric acid and fatal myocardial infarction: detection of prognostic cut-off values: The URRAH (Uric Acid Right for Heart Health) study. J Hypertens. 2020;38(3):412-9. doi:10.1097/HJH.0000000000002287.
149. Akashi N, Kuwabara M, Matoba T, et al. Hyperuricemia predicts increased cardiovascular events in patients with chronic coronary syndrome after percutaneous coronary intervention: A nationwide cohort study from Japan. Front Cardiovasc Med. 2023;9:1062894. doi:10.3389/fcvm.2022.1062894.
150. Alberti KG, Zimmet PZ. Definition, diagnosis and classification of diabetes mellitus and its complications. Part 1: diagnosis and classification of diabetes mellitus provisional report of a WHO consultation. Diabet Med. 1998;15(7):539-53. doi:10.1002/(SICI)1096-9136(199807)15:7<539::AID-DIA668>3.0.CO;2-S.
151. van der Velde M, Bello AK, Brantsma AH, et al. Do albuminuria and hs-CRP add to the International Diabetes Federation definition of the metabolic syndrome in predicting out-come? Nephrol Dial Transplant. 2012;27(6):2275-83. doi:10.1093/ndt/gfr634.
152. Astor BC, Matsushita K, Gansevoort RT, et al. Lower estimated glomerular filtration rate and higher albuminuria are associated with mortality and end-stage renal disease. A collaborative meta-analysis of kidney disease population cohorts. Kidney Int. 2011;79(12):1331-40.
153. Xia F, Liu G, Shi Y, Zhang Y. Impact of microalbuminuria on incident coronary heart disease, cardiovascular and all-cause mortality: a meta-analysis of prospective studies. Int J Clin Exp Med. 2015;8(1):1-9.
154. Inoue K, Streja E, Tsujimoto T, Kobayashi H. Urinary albumin-to-creatinine ratio within normal range and all-cause or cardiovascular mortality among U.S. adults enrolled in the NHANES during 1999-2015. Ann Epidemiol. 2021;55:15-23. doi:10.1016/j.annepidem.2020.12.004.
155. Claudel SE, Waikar SS, Schmidt IM, et al. The relationship between low levels of albuminuria and mortality among adults without major cardiovascular risk factors. Eur J Prev Cardiol. 2024;31(17):2046-55. doi:10.1093/eurjpc/zwae189.
156. Chronic Kidney Disease Prognosis Consortium; Matsushita K, van der Velde M, et al. Association of estimated glomerular filtration rate and albuminuria with all-cause and cardiovascular mortality in general population cohorts: a collaborative meta-analysis. Lancet. 2010;375(9731):2073-81. doi:10.1016/S0140-6736(10)60674-5.
157. van der Velde M, Matsushita K, Coresh J, et al. Lower estimated glomerular filtration rate and higher albuminuria are associated with all-cause and cardiovascular mortality. A collaborative meta-analysis of high-risk population cohorts. Kidney Int. 2011;79(12):1341-52. doi:10.1038/ki.2010.536.
158. Sehtman-Shachar DR, Yanuv I, Schechter M, et al. Normoalbuminuria-is it normal? The association of urinary albumin within the ‘normoalbuminuric’ range with adverse cardiovascular and mortality outcomes: A systematic review and meta-analysis. Diabetes Obes Metab. 2024;26(10):4225-40. doi:10.1111/dom.15752.
159. Writing Group for the CKD Prognosis Consortium; Grams ME, et al. Estimated Glomerular Filtration Rate, Albuminuria, and Adverse Outcomes: An Individual-Participant Data Meta-Analysis. JAMA. 2023;330(13):1266-77. doi:10.1001/jama.2023.17002.
160. Claudel SE, Verma A. Albuminuria in Cardiovascular, Kidney, and Metabolic Disorders: A State-of-the-Art Review. Circulation. 2025;151(10):716-32. doi:10.1161/CIRCULATIONAHA.124.071079.
161. Matsushita K, Coresh J, Sang Y, et al.; CKD Prognosis Consortium. Estimated glomerular filtration rate and albuminuria for prediction of cardiovascular outcomes: a collaborative meta-analysis of individual participant data. Lancet Diabetes Endocrinol. 2015;3(7):514-25. doi:10.1016/S2213-8587(15)00040-6.
162. Kidney Disease: Improving Global Outcomes (KDIGO) CKD Work Group. KDIGO 2024 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease. Kidney Int. 2024;105(4S): S117-S314. doi:10.1016/j.kint.2023.10.018.
163. Ruilope LM, Ortiz A, Lucia A, et al. Prevention of cardiorenal damage: importance of albuminuria. Eur Heart J. 2023;44(13):1112-23. doi:10.1093/eurheartj/ehac683.
164. Ortiz A, Arreola Guerra JM, Chan JCN, et al. Conference Participants. Preventing chronic kidney disease and maintaining kidney health: conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference. Kidney Int. 2025;108(4):555-71. doi:10.1016/j.kint.2025.04.005.
165. Ridker PM. A Test in Context: High-Sensitivity C-Reactive Protein. J Am Coll Cardiol. 2016;67(6):712-23. doi:10.1016/j.jacc.2015.11.03.
166. Ridker PM, Cook N. Clinical usefulness of very high and very low levels of C-reactive protein across the full range of Framingham Risk Scores. Circulation. 2004;109(16):1955-9. doi:10.1161/01.CIR.0000125690.80303.
167. den Engelsen C, Koekkoek PS, Gorter KJ, et al. High-sensitivity C-reactive protein to detect metabolic syndrome in a centrally obese population: a cross-sectional analysis. Cardiovasc Diabetol. 2012;11:25. doi:10.1186/1475-2840-11-25.
168. Xue Q, Wang Y, Zheng D, et al. Association between baseline and changes in high-sensitive C-reactive protein and metabolic syndrome: a nationwide cohort study and meta-analysis. Nutr Metab (Lond). 2022;19(1):52. doi:10.1186/s12986-022-00690-w.
169. Halcox JP, Roy C, Tubach F, et al. C-reactive protein levels in patients at cardiovascular risk: EURIKA study. BMC Cardiovasc Disord. 2014;14:25. doi:10.1186/1471-2261-14-25.
170. Emerging Risk Factors Collaboration; Kaptoge S, Di Angelantonio E, Lowe G, et al. C-reactive protein concentration and risk of coronary heart disease, stroke, and mortality: an individual participant meta-analysis. Lancet. 2010;375(9709):132-40. doi:10.1016/S0140-6736(09)61717-7.
171. Ridker PM, Figtree GA, Moorthy MV, et al. C-reactive protein and cardiovascular risk among women with no standard modifiable risk factors: evaluating the ‘SMuRF-less but inflamed’. Eur Heart J. 2026;47(3):306-14. doi:10.1093/eurheartj/ehaf658.
172. Arnold N, Goßling A, Weimann J, et al. Occurrence of coronary events in the absence of traditional risk factors: Understanding residual risk. Atherosclerosis. 2025;409:120475. doi:10.1016/j.atherosclerosis.2025.120475.
173. Markus MRP, Ittermann T, Mariño Coronado J, et al. Low-density lipoprotein cholesterol, lipoprotein(a) and high-sensitivity C-reactive protein are independent predictors of cardiovascular events. Eur Heart J 2025;46:3863-74. doi:10.1093/eurheartj/ehaf281.
174. Kraaijenhof JM, Nurmohamed NS, Nordestgaard AT, et al. Low-density lipoprotein cholesterol, C-reactive protein, and lipoprotein(a) universal one-time screening in primary prevention: the EPIC-Norfolk study. Eur Heart J. 2025;46:3875-84. doi:10.1093/eurheartj/ehaf209.
175. Ridker PM, Moorthy MV, Cook NR, et al. Inflammation, cholesterol, lipoprotein(a), and 30-year cardiovascular outcomes in women. N Engl J Med. 2024;391:2087-97.
176. Ridker PM, Rifai N, Clearfield M, et al. Measurement of C-reactive protein for the targeting of statin therapy in the primary prevention of acute coronary events. N Engl J Med. 2001;344:1959-65.
177. Ridker PM, Danielson E, Fonseca FA, et al. Reduction in C-reactive protein and LDL cholesterol and cardiovascular event rates after initiation of rosuvastatin: a prospective study of the JUPITER trial. Lancet. 2009;373(9670):1175-82. doi:10.1016/S0140-6736(09)60447-5.
178. Nissen SE, Lincoff AM, Brennan D, et al. Bempedoic acid and cardiovascular outcomes in statinintolerant patients. N Engl J Med. 2023;388:1353-64.
179. Ridker PM, Bhatt DL, Pradhan AD, et al. Inflammation and cholesterol as predictors of cardiovascular events among patients receiving statin therapy: a collaborative analysis of three randomised trials. Lancet. 2023;401:1293-301.
180. Ridker PM, Lei L, Louie MJ, et al. Inflammation and cholesterol as predictors of cardiovascular events among 13 970 contemporary high-risk patients with statin intolerance. Circulation. 2024;149:28-35.
181. Mazhar F, Faucon A-L, Fu EL, et al. Systemic inflammation and health outcomes in patients receiving treatment for atherosclerotic cardiovascular disease. Eur Heart J. 2024;45:4719-30.
182. Ridker PM, Everett BM, Thuren T, et al.; CANTOS Trial Group. Antiinflammatory Therapy with Canakinumab for Atherosclerotic Disease. N Engl J Med. 2017;377(12):1119-31. doi:10.1056/NEJMoa1707914.
183. Tardif JC, Kouz S, Waters DD, et al. Efficacy and Safety of Low-Dose Colchicine after Myocardial Infarction. N Engl J Med. 2019;381(26):2497-505. doi:10.1056/NEJMoa1912388.
184. Nidorf SM, Fiolet ATL, Mosterd A, et al. Colchicine in Patients with Chronic Coronary Disease. N Engl J Med. 2020;383(19):1838-47. doi:10.1056/NEJMoa2021372.
185. Mensah GA, Arnold N, Prabhu SD, et al. Inflammation and Cardiovascular Disease: 2025 ACC Scientific Statement: A Report of the American College of Cardiology. J Am Coll Cardiol. 2025: S0735-1097(25)07555-2. doi:10.1016/j.jacc.2025.08.047.
186. Mechanick JI, Christofides EA, Marchetti AE, et al. The syndromic triad of COVID-19, type 2 diabetes, and malnutrition. Front Nutr. 2023;10:1122203. doi:10.3389/fnut.2023.1122203.
187. Soares-Jr JM, Hayashida SAY, Marcondes JAM, et al. Influence of Phenotypes on the Metabolic Syndrome of Women with Polycystic Ovary Syndrome over a Six-Year Follow-Up in Brazil. Biomedicines. 2023;11(12):3262. doi:10.3390/biomedicines11123262.
188. Vera-Ponce VJ, Loayza-Castro JA, Zuzunaga-Montoya FE, et al. Associations between metabolic phenotypes and diabetes risk: A systematic review and meta-analysis. Endocrine and Metabolic Science. 2023;13:100142. doi:10.1016/j.endmts.2023.100142.
189. Ndumele CE, Rodriguez F, Dixon DL, et al. 2026 AHA/ACC/ADA/ASN Guideline for the Prevention, Detection, Evaluation, and Management of Cardiovascular-Kidney-Metabolic Syndrome: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. J Am Coll Cardiol. 2026;87(22S): e1889-e2007. doi:10.1016/j.jacc.2026.03.056.
190. Romeo S, Vidal-Puig A, Husain M, et al. Clinical staging to guide management of metabolic disorders and their sequelae: a European Atherosclerosis Society consensus statement. Eur Heart J. 2025;46(38):3685-713. doi:10.1093/eurheartj/ehaf314.
191. Hamooya BM, Siame L, Muchaili L, Masenga SK, Kirabo A. Metabolic syndrome: epidemiology, mechanisms, and current therapeutic approaches. Front Nutr. 2025;12:1661603. doi:10.3389/fnut.2025.1661603.
192. Ройтман А. П., Вавилова Т. В., Бугров А. В. и др. Референсные и целевые уровни мочевой кислоты у коморбидных пациентов: роль лаборатории в оценке и снижении сердечно-сосудистого риска (обзор литературы). Клиническая лабораторная диагностика. 2026;71(6):584-93. doi:10.51620/0869-2084-2026-71-6-584-593. EDN: HQMMWW.
193. Carlino I, Di Franco S, Colalillo N, et al. Across Clinical Profiles of Cardiorenal– Metabolic (CKM) Syndrome: A Phenotype-Driven Therapeutic Approach. Biomedicines. 2026;14(6):1289. doi:10.3390/biomedicines14061289.
194. Шляхто Е. В., Недогода С. В., Бабенко А. Ю. и др. Концепция междисциплинарного согласительного документа по кардиорено-гепато-метаболическому синдрому. Российский кардиологический журнал. 2025;30(1S):6533. doi:10.15829/1560-4071-2025-6533. EDN: USWGQQ.
195. Nadolsky K, Garvey WT, Agarwal M, et al. American Association of Clinical Endocrinology Consensus Statement: Algorithm for the Evaluation and Treatment of Adults with Obesity/ Adiposity-Based Chronic Disease — 2025 Update. Endocr Pract. 2025;31(11):1351-94. doi:10.1016/j.eprac.2025.07.017.
196. Durrer Schutz D, Busetto L, Dicker D, et al. European Practical and Patient-Centred Guidelines for Adult Obesity Management in Primary Care. Obes Facts. 2019;12(1):40-66. doi:10.1159/000496183.
197. Chong B, Jayabaskaran J, Jauhari SM, et al. Global burden of cardiovascular diseases: projections from 2025 to 2050. Eur J Prev Cardiol. 2025;32(11):1001-5. doi:10.1093/eurjpc/zwae281.
198. Zhu XY, Shi MQ, Jiang ZM, et al. Global, regional, and national burden of cardiovascular diseases attributable to metabolic risks across all age groups from 1990 to 2021: an analysis of the 2021 global burden of disease study data. BMC Public Health. 2025;25(1):1704. doi:10.1186/s12889-025-22702-7.
199. Chen Y, Himan HR, Yazicioglu Y, et al. Population estimates, trends, characteristics and prognostic outcomes of cardiovascular-kidney-liver-metabolic health: A population-based study. Am J Prev Cardiol. 2026;25:101405. doi:10.1016/j.ajpc.2025.101405.
200. Joynt Maddox KE, Elkind MSV, Aparicio HJ, et al. Forecasting the Burden of Cardiovascular Disease and Stroke in the United States Through 2050-Prevalence of Risk Factors and Disease: A Presidential Advisory From the American Heart Association. Circulation. 2024;150(4): e65-e88. doi:10.1161/CIR.0000000000001256.
201. Ding H, Jiang L, Zhao Y, et al. Associations between cardiovascular-kidney-metabolic syndrome staging and risks of all-cause and cardiovascular mortality: a systematic review and meta-analysis. Am J Prev Cardiol. 2026;25:101407. doi:10.1016/j.ajpc.2026.101407.
202. Tsai SP, Wen CP, Chan HT, et al. The effects of pre-disease risk factors within metabolic syndrome on all-cause and cardiovascular disease mortality. Diabetes Res Clin Pract. 2008;82(1):148-56. doi:10.1016/j.diabres.2008.07.016.
203. Lee YJ, Lee JH, Kim M, et al. Combined Pre-Hypertension, Pre-Diabetes, and Pre-Hyperlipidemia and Long-Term Cardiovascular Risk in Young Adults: A Nationwide Cohort Study. Eur J Prev Cardiol. 2026: zwag233. doi:10.1093/eurjpc/zwag233.
204. Hirata A, Uchida T. The Specific Health Checkups and Specific Health Guidance Program: A Strategy for the Prevention of Cardiovascular Disease in Japan. J Atheroscler Thromb. 2026;33(4):367-76. doi:10.5551/jat.RV22047.
205. Harrison JE, Weber S, Jakob R, Chute CG. ICD-11: an international classification of diseases for the twenty-first century. BMC Med Inform Decis Mak. 2021;21(Suppl 6):206. doi:10.1186/s12911-021-01534-6.
206. Ioakeim-Skoufa I, González-Rubio F, Aza-Pascual-Salcedo M, et al. Multimorbidity patterns and trajectories in young and middle-aged adults: a large-scale population-based cohort study. Front Public Health. 2024;12:1349723. doi:10.3389/fpubh.2024.1349723.
207. Ioakeim-Skoufa I, Ledesma-Calvo R, Moreno-Juste A, et al. Charting the Pathways of Cardiometabolic Multimorbidity: A Systematic Review of Clinical Trajectories. J Clin Med. 2025;14(8):2615. doi:10.3390/jcm14082615.
208. Ferris JK, Fiedeldey LK, Kim B, et al. A systematic review and meta-analysis of disease clusters in multimorbidity. Nat Commun. 2025;17(1):634. doi:10.1038/s41467-025-67372-6.
209. Molokhia M, Okoli GN, Redmond P, et al. Uncoded chronic kidney disease in primary care: a cross-sectional study of inequalities and cardiovascular disease risk management. Br J Gen Pract. 2020;70(700): e785-e792. doi:10.3399/bjgp20X713105.
210. Canaway R, Chidgey C, Hallinan CM, et al. Undercounting diagnoses in Australian general practice: a data quality study with implications for population health reporting. BMC Med Inform Decis Mak. 2024;24(1):155. doi:10.1186/s12911-024-02560-w.
211. Zhao M, Zhang J, Wang H, et al. Cardiovascular-Kidney-Metabolic Syndrome: Development of an ICD-10-CM Coding Framework. JMIR Diabetes. 2026;11: e91827. doi:10.2196/91827.